Revolution Medicines' experimental oral drug, daraxonrasib, has shown remarkable results in a Phase III clinical trial for people with advanced pancreatic cancer. The drug nearly doubled the typical length of survival compared to standard care, and is expected to be the first medication approved for these difficult-to-treat cancer cases. A decision from the Food and Drug Administration is expected within months. The trial's results show that darraxonrasIB is designed to broadly inhibit RAS variants, potentially allowing it to tackle a wide range of pancreatic cancers. While the median length of life on darxonrasb was 13.2 months, it is possible that the drug will be even more effective when started earlier.